Stempoint Capital LP Acquires 6,218 Shares of Dianthus Therapeutics, Inc. $DNTH

Stempoint Capital LP raised its stake in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) by 7.8% in the first quarter, Holdings Channel reports. The institutional investor owned 85,502 shares of the company’s stock after buying an additional 6,218 shares during the quarter. Dianthus Therapeutics accounts for about 1.4% of Stempoint Capital LP’s holdings, making the stock its 27th biggest position. Stempoint Capital LP’s holdings in Dianthus Therapeutics were worth $7,175,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also bought and sold shares of DNTH. Vestal Point Capital LP raised its position in Dianthus Therapeutics by 88.2% in the 2nd quarter. Vestal Point Capital LP now owns 3,200,000 shares of the company’s stock worth $59,616,000 after buying an additional 1,499,931 shares during the last quarter. Wellington Management Group LLP grew its position in shares of Dianthus Therapeutics by 3,366.9% during the third quarter. Wellington Management Group LLP now owns 2,577,662 shares of the company’s stock worth $101,431,000 after purchasing an additional 2,503,311 shares in the last quarter. Vanguard Group Inc. boosted its position in shares of Dianthus Therapeutics by 24.7% during the fourth quarter. Vanguard Group Inc. now owns 2,048,452 shares of the company’s stock worth $84,417,000 after acquiring an additional 406,254 shares during the last quarter. TCG Crossover Management LLC lifted its stake in Dianthus Therapeutics by 11.7% in the 3rd quarter. TCG Crossover Management LLC now owns 1,676,624 shares of the company’s stock worth $65,975,000 after purchasing an additional 175,000 shares in the last quarter. Finally, State Street Corp boosted its holdings in shares of Dianthus Therapeutics by 124.7% during the 4th quarter. State Street Corp now owns 1,507,619 shares of the company’s stock valued at $62,129,000 after purchasing an additional 836,571 shares during the last quarter. 47.53% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Dianthus Therapeutics

In related news, EVP Simrat Randhawa sold 26,530 shares of the stock in a transaction on Monday, June 1st. The stock was sold at an average price of $90.62, for a total transaction of $2,404,148.60. Following the sale, the executive vice president owned 4,000 shares in the company, valued at approximately $362,480. This represents a 86.90% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, EVP Ryan Savitz sold 31,249 shares of the firm’s stock in a transaction on Thursday, July 9th. The stock was sold at an average price of $101.03, for a total value of $3,157,086.47. Following the completion of the sale, the executive vice president owned 31,249 shares of the company’s stock, valued at approximately $3,157,086.47. This represents a 50.00% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 87,779 shares of company stock worth $7,985,235. Company insiders own 3.02% of the company’s stock.

Dianthus Therapeutics Price Performance

Shares of NASDAQ DNTH opened at $104.09 on Thursday. Dianthus Therapeutics, Inc. has a 1-year low of $18.08 and a 1-year high of $107.99. The business’s 50 day moving average is $91.76 and its two-hundred day moving average is $77.61. The stock has a market capitalization of $5.69 billion, a P/E ratio of -25.20 and a beta of 1.20.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its quarterly earnings data on Tuesday, May 5th. The company reported ($0.85) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.07) by $0.22. The business had revenue of $0.46 million during the quarter, compared to analyst estimates of $0.40 million. Dianthus Therapeutics had a negative return on equity of 27.30% and a negative net margin of 12,998.50%. As a group, equities research analysts anticipate that Dianthus Therapeutics, Inc. will post -3.82 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several brokerages have recently issued reports on DNTH. Wedbush lifted their target price on Dianthus Therapeutics from $103.00 to $105.00 and gave the stock an “outperform” rating in a report on Wednesday, May 6th. Guggenheim reaffirmed a “buy” rating on shares of Dianthus Therapeutics in a research note on Wednesday, June 10th. Wall Street Zen raised Dianthus Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, May 9th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Dianthus Therapeutics in a research report on Friday, July 17th. Finally, Raymond James Financial restated a “strong-buy” rating on shares of Dianthus Therapeutics in a research report on Wednesday, June 10th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, Dianthus Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $117.82.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.